Fueled by genetic changes due to cancer therapy itself, rogue cells may become very large with twice or quadruple the number of chromosomes found in healthy cells. Dr. Daruka Mahadevan of the Mays Cancer Center, home to UT Health San Antonio MD Anderson, seeks to find drugs that prevent or treat this problem.
A University of Pennsylvania-led team used an inhibitor of an enzyme called p38α kinase to suppress the spread of melanoma to the lungs in a mouse model.
Women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face questions about having surgery and radiation to the tumor in the breast (local therapy). Based on the results of the long-awaited E2108 randomized phase 3 trial at #ASCO20, these women should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit.
Oncologists who practice and teach at the Johns Hopkins Kimmel Cancer Center are calling on medical oncology training programs to invest substantially more time educating physicians about palliative care and how to talk to patients about 'bad news.'
A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.
A team of researchers led by Worcester Polytechnic Institute Provost Wole Soboyejo attached anti-cancer agents to the hormone LHRH to create drugs that targeted triple-negative breast cancer, which typically does not respond to conventional targeted cancer therapies. The researchers reported that the treatments reduced the size of tumors in mice with no signs of toxic side effects.
Response of liquid biopsies to approved drugs can help show resistance, predict response.
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC).
A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.